enGene (NASDAQ:ENGN) Receives Market Outperform Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of enGene (NASDAQ:ENGN - Free Report) in a research note released on Monday morning,Benzinga reports. The brokerage currently has a $18.00 target price on the stock.

ENGN has been the topic of several other reports. Raymond James initiated coverage on shares of enGene in a research report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 price target on the stock. Oppenheimer reaffirmed an "outperform" rating and set a $30.00 target price on shares of enGene in a report on Tuesday, September 24th. HC Wainwright assumed coverage on shares of enGene in a research report on Monday. They issued a "buy" rating and a $25.00 price target for the company. Morgan Stanley reissued an "overweight" rating and set a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Finally, Citizens Jmp raised enGene to a "strong-buy" rating in a report on Monday, November 18th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, enGene has an average rating of "Buy" and an average target price of $29.78.

enGene Stock Performance

Shares of NASDAQ:ENGN traded up $0.13 during trading on Monday, reaching $5.96. 131,078 shares of the stock were exchanged, compared to its average volume of 118,111. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The stock has a 50-day moving average price of $8.13 and a 200-day moving average price of $7.80. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a market cap of $263.53 million, a PE ratio of -10.28 and a beta of -0.78.

enGene (NASDAQ:ENGN - Get Free Report) last released its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. Research analysts expect that enGene will post -1.52 EPS for the current fiscal year.

Insider Transactions at enGene

In related news, CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the business's stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $5.70 per share, for a total transaction of $57,000.00. Following the completion of the transaction, the chief executive officer now directly owns 10,000 shares of the company's stock, valued at approximately $57,000. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Growth Opportunities F. Forbion purchased 11,844 shares of the stock in a transaction dated Monday, October 7th. The shares were bought at an average price of $6.55 per share, with a total value of $77,578.20. Following the completion of the acquisition, the insider now directly owns 2,469,833 shares of the company's stock, valued at approximately $16,177,406.15. This represents a 0.48 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 420,965 shares of company stock valued at $2,651,103. Corporate insiders own 13.70% of the company's stock.

Institutional Investors Weigh In On enGene

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wolverine Asset Management LLC acquired a new stake in shares of enGene during the third quarter valued at about $37,000. Point72 Asset Management L.P. raised its holdings in enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock valued at $4,376,000 after buying an additional 619,100 shares during the last quarter. SR One Capital Management LP acquired a new stake in enGene during the 2nd quarter worth approximately $4,715,000. Franklin Resources Inc. grew its holdings in enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock worth $7,854,000 after acquiring an additional 389,918 shares during the last quarter. Finally, Logos Global Management LP grew its holdings in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock worth $11,316,000 after acquiring an additional 400,000 shares during the last quarter. Institutional investors own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.